

# Tiziana Comito

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5108612/publications.pdf>

Version: 2024-02-01

64  
papers

2,235  
citations

236612

25  
h-index

233125

45  
g-index

65  
all docs

65  
docs citations

65  
times ranked

3019  
citing authors

#	ARTICLE	IF	CITATIONS
1	Is Stereotactic Body Radiation Therapy an Attractive Option for Unresectable Liver Metastases? A Preliminary Report From a Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 336-342.	0.4	168
2	Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 543-553.	1.2	145
3	The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1301-1309.	1.2	135
4	Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 313-322.	0.4	134
5	Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. <i>Radiation Oncology</i> , 2013, 8, 171.	1.2	98
6	Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review. <i>Radiotherapy and Oncology</i> , 2018, 129, 427-434.	0.3	98
7	SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. <i>Radiation Oncology</i> , 2013, 8, 148.	1.2	91
8	Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. <i>BMC Cancer</i> , 2014, 14, 619.	1.1	86
9	Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 295-301.	0.8	80
10	Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. <i>BMC Cancer</i> , 2017, 17, 829.	1.1	77
11	Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. <i>Radiation Oncology</i> , 2018, 13, 234.	1.2	73
12	Stereotactic body radiation therapy for liver metastases. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 190-7.	0.6	66
13	Hypo-fractionated stereotactic radiotherapy alone using volumetric modulated arc therapy for patients with single, large brain metastases unsuitable for surgical resection. <i>Radiation Oncology</i> , 2016, 11, 76.	1.2	59
14	Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. <i>PLoS ONE</i> , 2019, 14, e0210758.	1.1	58
15	Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. <i>Breast</i> , 2016, 26, 11-17.	0.9	51
16	Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. <i>Radiotherapy and Oncology</i> , 2019, 133, 220-226.	0.3	49
17	Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2019, 201, 70-76.	0.2	44
18	Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. <i>Radiation Oncology</i> , 2012, 7, 204.	1.2	38

#	ARTICLE	IF	CITATIONS
19	Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1507-1513.	1.2	35
20	Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery. <i>Cancer Research and Treatment</i> , 2017, 49, 20-28.	1.3	34
21	Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1399-1407.	3.3	33
22	Liver metastases and SBRT: A new paradigm?. <i>Reports of Practical Oncology and Radiotherapy</i> , 2015, 20, 464-471.	0.3	31
23	Hypofractionated stereotactic radiation therapy in skull base meningiomas. <i>Journal of Neuro-Oncology</i> , 2015, 124, 283-289.	1.4	31
24	Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 111-121.	0.4	30
25	Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1777-1783.	1.2	28
26	Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases. <i>World Journal of Surgery</i> , 2018, 42, 2651-2659.	0.8	27
27	Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1293-1299.	1.2	26
28	New Perspectives in the Treatment of Colorectal Metastases. <i>Liver Cancer</i> , 2017, 6, 90-98.	4.2	25
29	Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1795-1800.	1.2	20
30	Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapy. <i>BMC Cancer</i> , 2014, 14, 833.	1.1	19
31	Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 325-333.	1.0	19
32	Role of Stereotactic Body Radiation Therapy with Volumetric-Modulated Arcs and High-Intensity Photon Beams for the Treatment of Abdomino-Pelvic Lymph-Node Metastases. <i>Cancer Investigation</i> , 2016, 34, 348-354.	0.6	16
33	The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly. <i>British Journal of Radiology</i> , 2015, 88, 20150111.	1.0	15
34	Surgery Followed by Hypofractionated Radiosurgery on the Tumor Bed in Oligometastatic Patients With Large Brain Metastases. Results of a Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1095-1105.	0.4	15
35	The role of SBRT in oligometastatic patients with liver metastases from breast cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2017, 22, 163-169.	0.3	14
36	Moderate hypofractionated radiotherapy with volumetric modulated arc therapy and simultaneous integrated boost for pelvic irradiation in prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1301-1309.	1.2	14

#	ARTICLE	IF	CITATIONS
37	Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma. <i>British Journal of Radiology</i> , 2017, 90, 20170257.	1.0	14
38	Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature. <i>Breast</i> , 2018, 42, 31-37.	0.9	14
39	Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2469-2479.	1.2	14
40	Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. <i>British Journal of Radiology</i> , 2017, 90, 20170422.	1.0	13
41	Volumetric modulated arc therapy for thoracic node metastases: a safe and effective treatment for a neglected disease. <i>Oncotarget</i> , 2016, 7, 53321-53329.	0.8	13
42	Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2289-2297.	1.2	12
43	Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?. <i>Radiotherapy and Oncology</i> , 2020, 150, 184-190.	0.3	12
44	The Role of Stereotactic Ablative Radiotherapy in Oncological and Non-Oncological Clinical Settings: Highlights from the 7 <sup>th</sup> Meeting of AIRO's Young Members Working Group (AIRO Giovani). <i>Tumori</i> , 2014, 100, e214-e229.	0.6	12
45	What is the role of [11C]choline PET/CT in decision making strategy before post-operative salvage radiation therapy in prostate cancer patients?. <i>Acta Oncologica</i> , 2014, 53, 990-992.	0.8	11
46	Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. <i>British Journal of Radiology</i> , 2020, 93, 20190627.	1.0	11
47	Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 480-486.	1.1	10
48	Stereotactic Radiotherapy for Ultra-Central Lung Oligometastases in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 885.	1.7	10
49	Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 565-573.	1.7	9
50	Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 927-936.	1.2	9
51	Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma. <i>PLoS ONE</i> , 2018, 13, e0201992.	1.1	8
52	Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation. <i>British Journal of Radiology</i> , 2019, 92, 20190252.	1.0	8
53	Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 396-404.	1.0	8
54	Brain metastases from primary colorectal cancer: is radiosurgery an effective treatment approach? Results of a multicenter study of the radiation and clinical oncology Italian association (AIRO). <i>British Journal of Radiology</i> , 2020, 93, 20200951.	1.0	8

#	ARTICLE	IF	CITATIONS
55	Radiotherapy in the multidisciplinary treatment of liver cancer: a survey on behalf of the Italian Association of Radiation Oncology. <i>Radiologia Medica</i> , 2016, 121, 735-743.	4.7	7
56	Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 385-391.	1.0	7
57	Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity. <i>British Journal of Radiology</i> , 2019, 92, 20190021.	1.0	6
58	Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1227-1234.	1.2	5
59	Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3619-3625.	1.2	5
60	Radiomics-based prognosis classification for high-risk prostate cancer treated with radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 710-718.	1.0	5
61	Critical Re-Evaluation of a Failure Mode Effect Analysis in a Radiation Therapy Department After 10 Years. <i>Practical Radiation Oncology</i> , 2021, 11, e329-e338.	1.1	4
62	The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382098041.	0.8	2
63	EUS-guided placement of fiducial markers for image-guided radiotherapy in gastrointestinal tumors: A critical appraisal. <i>Endoscopic Ultrasound</i> , 2021, .	0.6	2
64	Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy. <i>Acta Oncologica</i> , 2022, 61, 553-559.	0.8	2